As the pan-European STOXX Europe 600 Index sees modest gains and key indices like Germany's DAX and Italy's FTSE MIB show positive momentum, European investors remain focused on geopolitical developments and economic indicators that could influence market dynamics. In this context, high-growth tech stocks in Europe are drawing attention for their potential to capitalize on technological advancements and innovation, making them noteworthy amid the current market conditions where strategic positioning can be crucial for navigating volatility.
Top 10 High Growth Tech Companies In Europe
| Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
| Hacksaw |
25.39% |
24.80% |
★★★★★★ |
| 2CRSI |
31.84% |
73.71% |
★★★★★★ |
| Pharma Mar |
17.60% |
31.67% |
★★★★★☆ |
| Bonesupport Holding |
23.24% |
33.79% |
★★★★★★ |
| CD Projekt |
31.67% |
26.86% |
★★★★★★ |
| KebNi |
26.87% |
82.69% |
★★★★★★ |
| Smartoptics Group |
23.15% |
46.46% |
★★★★★★ |
| SyntheticMR |
18.81% |
47.40% |
★★★★★☆ |
| BioArctic |
28.74% |
53.32% |
★★★★★★ |
| Sectra |
14.73% |
22.74% |
★★★★★☆ |
We're going to check out a few of the best picks from our screener tool.
Ependion
Simply Wall St Growth Rating:★★★★☆☆
Overview:Ependion AB, with a market cap of SEK4.79 billion, offers digital solutions for secure control, management, visualization, and data communication in industrial applications through its subsidiaries.
Operations:Ependion AB generates revenue primarily from its subsidiaries, with Westermo contributing SEK1.44 billion and Beijer Electronics (including Korenix) adding SEK843.70 million. The company focuses on providing digital solutions for industrial applications, emphasizing secure control, management, and data communication.
Ependion AB, demonstrating robust financial health in its recent quarterly results, reported a significant sales increase to SEK 597.31 million from SEK 545.06 million year-over-year, alongside a net income rise to SEK 40.52 million from SEK 32.01 million. This growth trajectory is underscored by an annual revenue growth rate of 10.3%, outpacing the broader Swedish market's near-stagnant growth rate of 0.1%. Furthermore, Ependion's earnings are expected to surge by approximately 25.8% annually over the next three years, substantially exceeding Sweden's average market growth of 8.7%. The company's commitment to innovation is evident from its participation in key industry forums such as the Redeye Investor Forum, signaling ongoing strategic initiatives under CEO Jenny Sjodahl's leadership that could further enhance its market position and financial performance.
-
Click here and access our complete health analysis report to understand the dynamics of Ependion.
-
Evaluate Ependion's historical performance by accessing our past performance report.
CD Projekt
Simply Wall St Growth Rating:★★★★★★
Overview:CD Projekt S.A., along with its subsidiaries, is involved in the production, publishing, and digital distribution of video games and related products in Poland, with a market capitalization of PLN23.24 billion.
Operations:The company's primary revenue stream comes from its CD PROJEKT RED segment, generating PLN878.01 million.
CD Projekt, a standout in the European tech scene, recently reported a notable uptick in its financial metrics. With annual revenue growth at 31.7% and earnings expected to surge by 26.9% annually, the company is outpacing the broader Polish market significantly. These results were bolstered by strategic presentations at key industry conferences such as JP Morgan European Technology and Pekao Technology & Consumer Conference, underlining its proactive approach in aligning with technological advancements and market expectations. Despite a slight dip in net income from PLN 111.8 million to PLN 106.2 million in Q1 2026 compared to the previous year, CD Projekt's robust pipeline and engagement in high-profile events are poised to sustain its growth trajectory well into the future.
-
Navigate through the intricacies of CD Projekt with our comprehensive health report here.
-
Gain insights into CD Projekt's historical performance by reviewing our past performance report.
Synektik Spólka Akcyjna
Simply Wall St Growth Rating:★★★★☆☆
Overview:Synektik Spólka Akcyjna offers products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine in Poland with a market capitalization of PLN2.33 billion.
Operations:The company generates revenue primarily from its Diagnostic and IT Equipment segment, which contributes PLN654.96 million, and the Production of Radio Pharmaceuticals segment, adding PLN54.90 million.
Synektik Spólka Akcyjna, amid a dynamic European tech landscape, recently showcased its strategic focus at the Erste The Finest CEElection Equity Investor Conference. This exposure aligns with its robust financial trajectory, where earnings are set to outpace the Polish market with an 11.9% annual increase and revenue growth projected at 6.1%. Notably, its R&D commitment is evident in its operations, crucial for sustaining innovation and competitive edge in healthcare technology—a sector where it has already achieved a remarkable earnings growth of 31.6% over the past year.
Taking Advantage
-
Access the full spectrum of 66 European High Growth Tech and AI Stocks by clicking on this link.
-
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
-
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Ready To Venture Into Other Investment Styles?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
-
Find companies with promising cash flow potential yet trading below their fair value .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OM:EPEN WSE:CDR and WSE:SNT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
